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Abstract
Hepatorenal syndrome is a functional renal disorder that occurs in patients with liver failure and
portal hypertension. It is characterized by progressive renal impairment secondary to marked renal
vasoconstriction that occurs in the presence of a predominance of vasodilatation in the extrarenal
circulation. In liver failure and portal hypertension, homeostatic abnormalities secondary to
disturbances of a multitude of neurohumoral factors are present. Hepatorenal syndrome likely
represents one end of the spectrum of these homeostatic abnormalities. Hepatorenal syndrome is
often precipitated by such events as volume contraction, sepsis (especially spontaneous bacterial
peritonitis), or the administration of potential nephrotoxic agents. Therefore, the mainstay in the
management of hepatorenal syndrome is to avoid the occurrence of such events, to have awareness
of their existence, and to treat them promptly when they occur. In established hepatorenal syndrome,
orthotopic liver transplantation is currently the treatment of choice. In patients waiting for a
transplant, a number of treatments have been shown to act as an effective bridge to liver grafting.
The same treatments have also been shown to prolong survival in patients who are not transplant
candidates. These include pharmacotherapy with the combined use of intravenous vasopressin
analogs and albumin infusion or oral midodrine and subcutaneous octreotide, intervention
procedures such as transjugular intrahepatic portosystemic stent-shunt, extracorporeal liver support
therapy such as the molecular absorbent recirculating system, and in patients with advancing
uremia, renal replacement therapy such as continuous venovenous hemofiltration.
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R E V I E W
A R T I C L E
INTRODUCTION
Hepatorenal syndrome (HRS) is a functional renal
disorder that occurs in patients with acute or chronic liver
disease, advanced hepatic failure,  and portal
hypertension. It is characterized by impaired renal
function and marked abnormalities in the arterial
circulation and activities of endogenous vasoactive
systems. In the kidney, there is marked vasoconstriction
that results in low glomerular filtration rate (GFR). In
the extrarenal circulation, there is a predominance of
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Figure 1 summarizes a simplified current view of the
pathogenetic events that lead to HRS. Liver failure and
portal hypertension increase circulating and vascular
levels of vasodilators including nitric oxide, glucagon and
other gut hormones, prostacyclin, and possibly false
neurotransmitters. These, together with opening up of
anatomic vascular shunts, lead to splanchnic and systemic
vasodilatation, which is thought to be the initiating event
in the homeostatic disturbances accompanying advanced
liver disease. Peripheral vasodilatation decreases vascular
filling and reduces the effective arterial blood volume
(EABV). The subsequent stimulation of the central
volume receptors leads to compensatory increases in
arginine-vasopressin and in the activities of the renin-
angiotensin system (RAAS) and sympathetic nervous
system (SNS), which help to restore EABV. This
restoration is achieved in patients with compensated
cirrhosis but not in patients with decompensated cirrhosis.
In the latter group of patients, increasing severity of the
homeostatic abnormalities, combined with a progressive
decrease in plasma oncotic pressure consequent to
decreased albumin synthesis by the diseased liver, causes
an imbalance of the Starling equilibrium, resulting in
ascites and edema formation. The resultant sequestration
of fluid in the peritoneal and interstitial space aggravates
vascular underfilling, lowers systemic mean arterial blood
Figure 1. The pathogenesis of hepatorenal syndrome.
arteriolar dilatation, which results in reduction of the total
systemic vascular resistance and in arterial hypotension.
The functional nature of the renal disorder was
established by studies that showed that kidneys from
patients with HRS function normally after being
transplanted into patients with chronic renal failure and
that renal failure is rapidly reversed after successful
orthotopic liver transplantation (OLT). Since its first
detailed description by Hecker and Sherlock more than
50 years ago, numerous studies have focused on a better
understanding of its pathogenesis, but until recently,
medical therapy (apart from OLT) has been uniformly
unsuccessful. Because of lack of organ donors,
nephrologists are increasingly being consulted by liver
transplant surgeons to manage patients with HRS with a
hope of prolonging their lives until a donor can be found.
This review summarizes the current knowledge on the
pathogenesis, diagnosis, and treatment of HRS.
PATHOGENESIS
The renal and systemic hemodynamic changes that occur
in HRS are the result of complex interactions among a
multitude of neurohumoral disturbances (1). Hepatorenal
syndrome likely represents one end of the spectrum of
homeostatic abnormalities that accompany liver failure
and portal hypertension.
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pressure (MAP), and leads to further nonosmotic release
of arginine-vasopressin (hence the tendency for
hyponatremia) and continuous stimulation of the RAAS
and SNS. The SNS activity is further enhanced by
stimulation of the hepatorenal neural reflex arc as portal
hypertension progresses. Progressive liver failure and
portal hypertension also lead to increased levels of several
potent circulating or locally produced renal vasocon-
strictors that are released in response to endotoxemia or
oxidant stress. These include endothelins, leukotrienes,
thromboxanes, platelet activating factors, and F2-
isoprostanes (noncyclooxygenase-derived prostanoids
produced in vivo as products of free radical-catalyzed lipid
peroxidation). These, together with increasing renal SNS
activity, are thought to lead to the progressive renal
vasoconstriction that characterizes HRS. Normally, the
effect of renal vasoconstrictors is counterbalanced by the
reactive intrarenal production of several vasodilators,
which include prostaglandins, prostacyclin, and
kallikrein. It is postulated that HRS develops when the
balance of activities between the renal vasoconstrictors
and intrarenal vasodilators finally breaks down. The
likelihood that this will occur increases with progressive
deterioration in liver function or increasing severity of
portal hypertension and is precipitated by events that
lead to further volume contraction and reduction of the
EABV, eg, spontaneous bacterial peritonitis or by
 the administration of substances, eg, nonsteroidal
antiinflammatory drugs (NSAIDs) that further suppress
intrarenal generation of vasodilators (eg, prostaglandins).
CLINICAL PRESENTATION,
DIAGNOSIS, AND NATURAL
HISTORY
There are two common clinical presentations of HRS.
An acute form (type 1) is characterized by rapid
spontaneous deterioration in renal function defined as
doubling of serum creatinine to a level more than 2.5
mg/dL (>221 mmol/L) or a 50% or more reduction of
the baseline creatinine clearance in less than 2 weeks.
This is most often observed in patients with acute liver
failure, acute alcoholic hepatitis, or acute decom-
pensation on a background of cirrhosis. This group of
patients tends to have severe jaundice and coagulopathy.
Acute decompensation may be precipitated by bacterial
infection (including spontaneous bacterial peritonitis),
gastrointestinal bleeding, vigorous diuretic therapy, or
abdominal paracentesis. A chronic form (type 2) is
characterized by insidious onset and slowly progressive
deterioration in renal function. This is most often
observed in patients with decompensated cirrhosis and
portal hypertension. This group of patients tends to be
less severely jaundiced and has refractory ascites.
The diagnostic criteria of HRS have recently been
updated by the International Ascites Club (Table 1) (2).
The diagnosis of HRS is mainly one of exclusion (see
major criteria, Table 1), although measurement of urinary
electrolytes and osmolarity and plasma sodium may
provide supportive evidence for its occurrence. Hepa-
torenal syndrome should be suspected in any patient with
acute or chronic liver disease with advanced liver failure
and portal hypertension who develops progressive renal
insufficiency as reflected by an increasing serum
creatinine and blood urea nitrogen level or by decreasing
creatinine clearance. Significant renal insufficiency may
be present despite a normal serum creatinine or blood
urea nitrogen, because these patients are frequently
malnourished, with reduced lean body mass, and often
have a low urea generation rate because of liver failure
and low protein intake. Severe hyperbilirubinemia, which
is often present in patients with HRS, interferes with the
Table 1. Diagnostic criteria for hepatorenal syndrome.
Major criteria
1. Chronic or acute liver disease with advanced hepatic failure and portal hypertension.
2. Low GFR as indicated by serum creatinine >1.5 mg/dL (135 µmol/L) or 24-hour creatinine clearance <40 mL/min.
3. Absence of shock, ongoing bacterial infection, and current or recent treatment with nephrotoxic drugs.
4. Absence of gastrointestinal fluid losses (repeated vomiting or intense diarrhea).
5. Absence of renal fluid losses (weight loss >0.5 kg/day for 5 days in patients with ascites without peripheral edema or >1 kg/day in patients
with peripheral edema).
6. No sustained improvement in renal function (decrease in serum creatinine to ≤1.5 mg/dL [135 µmol/L] or increase in creatinine clearance
to ≥40 mL/min) after diuretic withdrawal and expansion of plasma volume with 1.5 L of isotonic saline.
7. Proteinuria <0.5 g/day and no ultrasonographic evidence of obstructive uropathy or parenchymal renal disease.
Additional criteria
1. Urine volume <500 mL/day.
2. Urine sodium <10 mmol/day.
3. Urine osmolarity greater than plasma osmolarity.
4. Urine red blood cells <50 per high power field.
5. Serum sodium concentration <130 mmol/L.
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measurement of serum creatinine, and in these patients,
alternative methods (eg, [125I] iothalamate, [51Cr] labeled
ethylenediaminetetraacetic acid, or inulin clearance) may
be needed to measure GFR accurately.
Pseudohepatorenal syndrome (Table 2) is usually easy
to exclude, because the etiological agent is frequently
known and both renal and liver functional abnormalities
are often found at first clinical presentation, whereas
evidence of advanced liver failure and portal hyper-
tension is usually not initially present. This is in contrast
to HRS, which invariably occurs after liver failure and
portal hypertension are fully established and frequently
develops when the patient is undergoing treatment for
these conditions or their complications in the hospital.
The probability of developing HRS in cirrhotic patients
is estimated at 18% at 1 year and 39% at 5 years (3).
Neither the etiology (alcoholic versus nonalcoholic) nor
the Child-Pugh score has predictive value on the
incidence of HRS. A multivariate analysis showed that
there are only three independent predictors of HRS: low
serum sodium concentration, high serum renin activity,
and absence of hepatomegaly (3). Abnormal renal duplex
Doppler ultrasonography (resistive index >0.7) has also
been shown recently to be an independent predictor of
the occurrence of HRS.
The prognosis of HRS is extremely poor. Without OLT,
the mortality rate is between 80% and 95%, depending
on the etiology of the underlying liver disease. Recovery
in renal function coincides with recovery of liver function
and liver regeneration. Renal failure is infrequently an
immediate cause of death, and most patients succumb to
the other complications of liver failure and portal
hypertension such as hepatic encephalopathy,
gastrointestinal bleeding, and sepsis.
TREATMENT
If one accepts the hypothesis that HRS represents one
end of the spectrum of the homeostatic abnormalities in
liver failure and portal hypertension and is precipitated
by such events as volume contraction, sepsis, or the
administration of potential nephrotoxic agents, it follows
that a major focus of treatment must be to avoid the
occurrence of such events, to have high awareness of
their existence, and to treat them promptly when they
occur. In patients with decompensated liver disease, the
common events that lead to volume contraction include
gastrointestinal bleeding, injudicious use of lactulose (for
treatment of hepatic encephalopathy) resulting in profuse
diarrhea, and overrigorous diuretic therapy and/or
paracentesis for the treatment of ascites. To avoid the
latter, a stepwise approach for the treatment of ascites is
recommended and has recently been published (4). In
these patients, the threshold for antibiotic therapy for
suspected sepsis should be low. Spontaneous bacterial
peritonitis must be excluded by regular examination of
ascites fluid and treated not only with broad-spectrum
antibiotics, but also with albumin infusion because the
latter has been shown to prevent the subsequent
development of HRS (5). The use of potential
nephrotoxic agents including angiotensin-converting
enzyme inhibitors, NSAIDs, aminoglycosides, and
radiologic contrast media should be avoided as far as
possible. Therapeutic agents (eg, β blockers and
somatostatin) that are used for the treatment of bleeding
esophageal and gastric varices may lead to a reduction
of GFR, and their use must be monitored carefully.
Figure 2 is an algorithm for the management of HRS.
Currently, there is no established treatment for HRS
except OLT. In view of the poor prognosis of HRS
without liver transplantation and because the diagnosis
of HRS is mainly one of exclusion, conditions that mimic
Infections
Drugs
Toxins
Systemic disease
Circulatory failure
Malignancy
Congenital and inherited disorders
Miscellaneous disorders
EBV = Epstein-Barr virus; HIV = human immunodeficiency virus; HELLP syndrome = type of severe preeclampsia involving hemolysis,
elevated liver function, and low platelets.
Table 2. Causes of pseudohepatorenal syndrome.
Sepsis (including liver abscess), leptospirosis, brucellosis, tuberculosis, EBV, HIV, hepatitis A,
B, and C viral infection, and schistosomiasis.
Tetracycline, rifampicin, sulphonamides, phenytoin, allopurinol, methoxyflurane, fluroxene,
methotrexate (high dose), acetaminophen (overdose).
Carbon tetrachloride, trichloroethylene, chloroform, elemental phosphorus, arsenic, copper,
chromium, barium, amatoxin, raw carp bile toxins.
Sarcoidosis, Sjögren syndrome, systemic lupus erythematosus, vasculitis, cryoglobulinemia, and
amyloidosis.
Hypovolemic or cardiogenic shock.
Lymphoma and leukemia.
Polycystic kidney and liver disease, nephronophthisis, and congenital hepatic fibrosis.
Fatty liver of pregnancy, preeclampsia and HELLP syndrome, Reye syndrome, and cirrhotic
glomerulonephropathy.
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HRS and that are more amenable to treatment or have a
better prognosis must be diligently excluded. Once the
diagnosis of HRS is made, the patients should be assessed
for their suitability for OLT. If they are suitable
candidates, they should be put onto the urgent waiting
list for cadaveric liver transplantation. In places where
cadaveric donor livers are scarce and where the surgical
expertise is available, a search for a suitable living donor
should also be explored. In patients who are potential
transplant candidates, treatments that have been shown
to be potentially useful for HRS should be instituted as a
bridge to OLT. These include pharmacotherapy,
interventional procedures, extracorporeal liver support
therapy, and in patients with advancing uremia, renal
replacement therapy. In patients who are not transplant
candidates, the use of these forms of therapy is more
controversial, but recent studies have shown that
prolonged survival in terms of months may be achievable
even in some of these patients.
Pharmacotherapy
From a pathogenetic viewpoint, the appropriate form of
pharmacotherapy for HRS would be the administration
of an agent, or a combination of agents, that induces
simultaneous renal vasodilatation and splanchnic
vasoconstriction. The former effect would theoretically
alleviate renal cortical vasoconstriction, a functional
hallmark of HRS, whereas the latter would reduce portal
pressure and restore a previously depressed EABV
resulting from peripheral vasodilatation back to normal
values. This in turn would reduce renal SNS activity and
suppress the generation of circulating and intrarenal
vasoconstrictors. This agent(s) may achieve its
therapeutic effect either through a direct vascular action
or by blocking the action of putative vasoactive
substances.
Nonspecific vasodilators (eg, acetylcholine and
papaverine) and α-adrenergic blockers (eg, phentolamine)
infused intra-arterially at low dose to patients with HRS
increase renal blood flow in some patients, but they do
not enhance GFR. These agents, when given at higher
intra-arterial dose or as intravenous infusion, invariably
cause systemic hypotension and their use in HRS is,
therefore, relatively contraindicated.
The observation that the administration of NSAIDs often
precipitates HRS in patients with decompensated
cirrhosis suggests an important role of intrarenal
prostaglandins in modulating renal hemodynamics in
these patients. However, intravenous or intraarterial
infusion of prostaglandin E1 has not been shown to
improve the GFR, free water clearance, or sodium
excretion in HRS, whereas a beneficial effect of oral
misoprostol (a prostaglandin E2 analog) in this condition
is not proven.
Intravenous and intraarterial dopamine given at a
subpressor dose acts as an intrarenal vasodilator and has
been used in the treatment of HRS with limited success
Figure 2. Algorithm for the management of hepatorenal syndrome.
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(6). Although dopamine increased cortical blood flow
and improved the angiographic appearance in these
patients, GFR did not consistently improve. Despite this,
dopamine remains a popular choice of pharmacologic
agents to use in HRS until recently when more effective
agents began to emerge.
Vasopressin analogs have recently attracted the most
attention as potential therapeutic agents in HRS.
Vasopressin has a preferential vasoconstrictor action on
the splanchnic versus the renal vascular bed and its use
could theoretically reverse splanchnic vasodilatation
without compromising renal perfusion. Ornipressin (8-
ornithine vasopressin) and terlipressin (triglycyl-lysine-
vasopressin) are synthetic polypeptide analogs of
arginine-vasopressin that have equipotent vasoconstrictor
activity to the parent compound but have markedly
reduced antidiuretic properties. Short-term administration
of these agents has been shown to increase MAP, reduce
SNS and renin activities, and increase renal blood flow
and GFR (7,8). Prolonged intravenous administration of
ornipressin in combination with daily albumin infusion
reversed HRS (type unspecified) in four of eight patients
(8), whereas the administration of ornipression (in
addition to and after the failure of dopamine infusion
given at a subpressor dose) until reversal of HRS or the
development of side effects has been shown to reverse
type 1 HRS in four of seven patients (9). Recurrence of
HRS after successful treatment was uncommon and was
observed in two patients in the latter study. Of these two
patients, retreatment was successful in one. The longest
patient survival after treatment without OLT was 8 months
(9). The main limitation of treatment was ischemic
complications, which was observed in five of these 15
patients and included intestinal ischemia, tongue necrosis,
and ventricular arrhythmia. In a recent pilot study,
terlipressin given as an intravenous bolus at 0.5 to 1 mg
every 4 hours in combination with daily albumin infusion
was shown to successfully reverse HRS (6 with type 1
and 3 with type 2) in seven of nine patients with the
longest survivor living up to 4 months without OLT and
without any severe ischemic complication that
necessitated early termination of treatment (10). If this
finding is confirmed by further studies, terlipressin may
prove to be currently the most convenient and safest
vasopressin analog to be used in the treatment of HRS.
Vasoconstrictors apart from vasopressin analogs have
also been used in the treatment of HRS. Intravenous
metaraminol, a synthetic sympathomimetic agent with
both α- and β-agonist actions, infused at an initial rate
to increase MAP by 30 to 40 mm Hg, increases peripheral
vascular resistance and improves water and sodium
excretion and GFR. However, the proarrhythmogenic
effect of this agent greatly limits its use. Intravenous
norepinephrine, which increases the MAP by 10 to 20
mm Hg, has no effect on renal blood flow and GFR and
reduces water and sodium excretion. Similarly, the short-
term administration of midodrine, an orally active α-
mimetic drug, results in an increase in MAP and systemic
vascular resistance and a reduction in plasma renin activity
but no improvement in renal blood flow or GFR (11).
Apart from the use of pharmacologic agents with direct
vascular action, specific inhibitors or antagonists of
endogenous vasoactive substances thought to be
important in the pathogenesis of HRS have been studied
for their therapeutic benefit. Angiotensin converting
enzyme inhibition and angiotensin blockade with
saralasin lead to profound hypotension and adversely
affect renal function and this is, therefore, relatively
contraindicated in HRS. This underscores the important
adaptive role of RAAS in maintaining systemic
hemodynamics in this condition. Inhibition of
thromboxane A2 generation using dazoxiben, a specific
thromboxane synthetase inhibitor, fails to improve renal
function in patients with HRS. Because thromboxane
inhibition leads to accumulation of the prostaglandin
endoperoxides PGG2 and PGH2, which mimic the renal
effect of thromboxane A2 by interacting with the same
receptor, this cannot be used as conclusive evidence
against a therapeutic role of thromboxane blockade in
HRS. A preliminary short-term study showed that a
specific endothelin A receptor antagonist increased renal
blood flow and GFR in three patients with HRS in the
absence of any change of systemic vascular resistance
and cardiac output, but no long-term survival data were
available and the finding has yet to be confirmed by a
follow-up study (12). In another preliminary study,
improvement of renal function and prolonged survival
(58% at 3 months) was observed after intravenous
infusion of N-acetylcysteine in 12 patients with HRS (13).
This occurred without demonstrable improvement of liver
function and systemic hemodynamics and presumably
works by relieving the oxidant stress that accompanies
portal hypertension, portosystemic shunting, and liver
failure thereby reducing the level of circulating and
intrarenal vasoconstrictors. Finally, octreotide, which is
an inhibitor of glucagon release but, unlike somatostatin,
has no adverse effect on renal hemodynamic and function,
was recently shown in a preliminary study to improve
renal function and urine output in four of five patients
with HRS with one patient surviving up to 5 months while
being maintained on a subcutaneous tapering dose (14).
To achieve simultaneous intrarenal vasodilatation and
systemic and splanchnic vasoconstriction, combinations
of intravenous prostacyclin and norepinephrine and low-
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dose dopamine and norepinephrine have been used for
the treatment of HRS with limited success. Recently, a
combination of oral midodrine and subcutaneous
octreotide was shown to be successful in reverting type
1 HRS in all of five treated patients compared with only
one of eight patients treated with subpressor dose
dopamine. The longest survivor lived for 15.5 months
without OLT. Minimal side effects were observed and
included tingling and goose bumps in two patients and
diarrhea in one patient. Reversion of HRS coincided with
an increase in mean blood pressure and a reduction in
plasma serum renin activity, aldosterone, antidiuretic
hormone, glucagon, and nitrite and nitrate levels (15).
Interventional procedures
In patients with HRS and tense ascites, paracentesis of 2
L of ascitic fluid reduces intra-abdominal pressure. This
is associated with a parallel decline in the pressure of
the hepatic vein and inferior vena cava (and presumably
the renal vein) and a transient increase in renal blood
flow, GFR, and urine flow rate (16). The lack of a
sustained renal hemodynamic response to paracentesis
is partly attributed to the reaccumulation of ascites fluid
and partly to volume contraction because of redistribution
of fluid from the vascular to the peritoneal space. This
may be overcome by the creation of a peritoneovenous
shunt (PVS).
Leveen peritoneovenous shunt
In 1974, Leveen designed a one-way pressure-activated
valve that could be implanted to create a permanent shunt
between the peritoneal cavity and the superior vena cava
for the treatment of ascites. Since then, several case
reports and clinical studies have described reversal of
HRS after the implantation of this shunt. However, in
many of these earlier reports, the diagnosis of HRS was
not well documented and some of these patients may
have had prerenal azotemia instead of HRS. Two recent
randomized controlled studies comparing PVS and
medical therapy in the treatment of HRS showed that
renal function seems to be better preserved in patients
receiving a PVS, but survival is only minimally or not
affected (17,18). Because PVS is not without side effects,
which include fever, disseminated intravascular
coagulation, shunt occlusion, infection, and ascites leak,
and it has a reported operative mortality rate of 26% and
a morbidity rate of more than 65%, its use in HRS is not
generally recommended.
Transjugular intrahepatic portosystemic stent-
shunt
Portal hypertension has a central role in the pathogenesis
of the homeostatic abnormalities in cirrhosis and hepatic
failure and in HRS. Early studies have shown that side-
to-side portocaval shunt may improve renal function in
patients with HRS, but the high operative mortality
precludes its use in this group of patients. Transjugular
intrahepatic portosystemic stent-shunt (TIPS) is a
recently described technique in which a metallic stent is
used to reinforce a parenchymal track created by balloon
dilatation between a branch of the hepatic vein and a
branch of the portal vein. In experienced hands, this
technique is associated with an operative mortality rate
of 1% to 2% and a morbidity rate of 10%. Procedure-
related complications include intra-abdominal bleeding,
cardiac arrhythmia, fever, shunt migration and
thrombosis, hemolytic anemia, fever, infection, and
reac t ion  to  rad iocon t ras t  media  ( inc lud ing
nephrotoxicity) and the resultant diversion of portal blood
flow from the liver to the systemic circulation may result
in transient deterioration of liver function and
development of encephalopathy. The successful
application of TIPS to the treatment of HRS is supported
by both short-term and long-term studies (19,20).
Reversal of HRS was associated with a decrease in SNS
and RAAS activity, which indicates re-expansion of a
previously depressed EABV (19). In a recent phase II
long-term study (20), improvement of renal function was
observed in 31 nontransplantable cirrhotic patients with
HRS but without severe liver failure (bilirubin <15 mg/
dL, Child-Pugh scores <12, and absence of spontaneous
severe encephalopathy) in whom limited portal
decompression was achieved using 8 to 10 mm stents.
For the whole group, the survival rates were 81%, 71%,
48%, and 35% at 3, 6, 12, and 18 months and for 14
patients with type 1 HRS, they were 64%, 50%, and 20%
at 3, 6, and 12 months. There was one procedure-related
death. Shunt stenosis and occlusion were encountered
in seven patients in whom patency was reestablished in
six patients by balloon dilatation or stent prolongation.
Transient deterioration of liver function and development
or worsening of hepatic encephalopathy were observed
in 11 patients.
Extracorporeal liver support therapy
Extracorporeal liver support therapy has been used as a
bridge to OLT and utilizes either biological or
nonbiological methods. The biological method uses
hepatocytes or whole liver organ from a human or animal
source in an ex vivo perfusion system, whereas the
nonbiological methods have included hemodialysis,
hemofiltration, plasma exchange, and hemoperfusion
through charcoal or other absorbents. Recently, in a
prospective randomized controlled trial, a molecular
adsorbent recirculating system, a modified dialysis
method using an albumin-containing dialysate that is
recirculated and perfused online through charcoal and
anion-exchanger columns, was shown to effectively
85
Hong Kong J Nephrol 2002;4(2):78-86. IKP CHENG
remove strongly albumin-bound toxic metabolites (ie,
bilirubin and bile acids) and to improve renal function
and prolong survival in eight patients with type 1 HRS
with severe liver failure (bilirubin >15 mg/dL) compared
with five untreated patients without any demonstrable
side effects (21). Molecular adsorbent recirculating
system treatment was associated with a reduction in
plasma renin activity, which was partly attributed to
direct removal but mainly attributed to an increase in
EABV secondary to an increased systemic vascular
resistance (22). The latter was in turn hypothesized to
be attributed to the removal of nitric oxide, which is
transported primarily bound to albumin as an S-
nitrosothiol.
Renal replacement therapy
Hemodialysis and peritoneal dialysis have been used for
the treatment of advancing uremia in patients with HRS,
but both are fraught with difficulties. Systemic
hypotension, which is invariably present, often means
that conventional hemodialysis is not feasible or can only
be performed with difficulty. The presence of large
amounts of ascites creates a huge “dead space”: that
reduces the efficiency of peritoneal dialysis. This may
be overcome by complete drainage of the abdominal fluid
between cycle exchange, but this would result in
substantial derangement of body fluid distribution, with
resultant hypotension. Continuous arteriovenous or
venovenous hemofiltration has been advocated for the
treatment of advancing uremia in HRS (23). The
continuous nature of the procedure together with lack of
osmotic shifts allow adequate removal of fluid and
uremic toxins with minimal hemodynamic compromise.
In addition, this allows the administration of nutritional
support, which is often vital to the survival of these
patients and would optimize their condition before OLT.
Furthermore, continuous hemofiltration is associated
with a decrease in intracranial pressure in patients with
HRS, whereas an increase is observed with intermittent
hemofiltration or hemodialysis. It is, therefore, also safer
to use in patients who have severe hepatic encepha-
lopathy. Although continuous hemofiltration is generally
recommended for patients with HRS, this procedure
requires continuous anticoagulation and, if lactate is used
as the buffer in the replacement fluid, inadequate
metabolism by the diseased liver can result in persistent
metabolic acidosis. The requirement for anticoagulants
may be reduced or completely abolished by giving the
replacement fluid in the predilutional mode. In patients
who have poor liver function, bicarbonate instead of
lactate should be used as the buffer for the replacement
solution. In liver transplant candidates, the site of dialysis
catheter placement should be carefully chosen, so the
right jugular and right femoral veins may be preserved
for cannulation when going into bypass at the time of
liver transplantation.
Orthotopic liver transplantation
Orthotopic liver transplantation is the only definitive
treatment for patients with HRS. A recent study compared
the clinical outcome of OLT in 56 patients with HRS
with that of 513 patients without HRS under immuno-
suppression based on steroid and cyclosporine
(cyclosporin A) (24). The patient and graft survival rates
were slightly lower in the HRS group compared with
the non-HRS group (60% vs 68% and 51% vs 61%,
respectively, at 5 years). Although renal function
improved after transplantation in HRS patients, it never
reached a level of function demonstrable in non-HRS
patients. The HRS group required a longer stay in an
intensive care unit, longer hospitalization, and more
dialysis treatment after transplantation; however,
pretransplant or post transplant dialysis did not affect
the clinical outcome. The incidence of end-stage renal
disease in the HRS group was 7% compared with 2% in
the non-HRS group. There was no significant difference
in the retransplantation rate and no difference in the long-
term liver function between the two groups. It would
seem, therefore, that OLT is associated with an acceptable
renal and liver outcome and is the treatment of choice
for patients with HRS.
Therapeutic strategy and choice of
treatment modalities
Although OLT is undoubtedly the treatment of choice
for patients with HRS, there are now several therapeutic
strategies that are promising in the treatment of HRS
(see above). These treatments may be used as a bridge
to OLT, in which case, they may improve the renal
outcome after successful OLT. In patients who are not
transplant candidates, these treatments are their only
chance for increased survival, and in some cases, may
improve their condition to an extent that may allow them
to be reconsidered for transplantation. The choice of
therapeutic modalities would depend on the availability
of resources and expertise on one hand and the severity
of underlying renal and liver failure and the general
condition of the patient on the other. In patients with
relatively well preserved liver function (bilirubin <15
mg/dL) with no or mild hepatic encephalopathy,
pharmacotherapy or TIPS would be the therapy of choice,
whereas in those with severe liver failure and hepatic
encephalopathy, the molecular adsorbent recirculating
system should be considered as a therapeutic option. In
patients with advancing renal failure, continuous
venovenous hemofiltration is the treatment of choice and
may be combined with the therapeutic modalities
previously mentioned.  Among the numerous
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pharmacotherapies, the regime of intravenous ornipressin
or terlipressin combined with daily albumin infusion and
that of oral midodrine combined with subcutaneous
octreotide seem most promising. The latter regime has
the advantage of home treatment.
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